High Yield Markets
  • World News
  • Politics
  • Investing
  • Stock
  • Editor’s Pick
Politics

Dr. McCullough Weighs In: The History & Future of GLP-1s

by March 29, 2025
March 29, 2025

(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Gateway Pundit. We appreciate your support!)

In a recent article by Dr. Peter McCullough, he explores the evolution of GLP-1 receptor agonists and their expanding role beyond diabetes treatment.

The journey began in 2005 with the FDA approval of exenatide (Byetta), setting the stage for a new class of medications that regulate blood sugar and appetite.

A Timeline of GLP-1 Advancements:

2005 – Exenatide (Byetta) approved for type 2 diabetes
2010 – Liraglutide (Victoza) enters the market
2017 – Semaglutide (Ozempic & oral Rybelsus) gains approval
2022 – Tirzepatide (Mounjaro) emerges as a dual-receptor agonist

These drugs influence key metabolic pathways, offering benefits for both diabetes and weight loss. However, they come with limitations—most require injections, clinical oversight, and ongoing prescriptions.

The Next Step: Retatrutide & The Power of Triple-Receptor Agonism

As Dr. McCullough discusses, retatrutide (LY3437943) represents the next evolution in GLP-1 therapies, targeting three key receptors:

– GLP-1 for appetite control & glucose regulation
– GIP to enhance insulin sensitivity
– Glucagon to promote fat metabolism

While injectable retatrutide is still under clinical investigation, early data suggests it is more effective than its predecessors. However, many individuals want a more flexible, private, and patient-controlled solution for weight loss.

Introducing DROP: A Revolutionary Approach to Weight Management

The Wellness Company developed DROP — an oral retatrutide formula — designed to support metabolic health without the barriers of traditional GLP-1 therapies.

Encapsulated in liposomes for enhanced absorption, DROP provides an alternative solution for those seeking appetite control and weight management in a non-injectable form.

If you’ve considered GLP-1 treatments but want a more discreet, adaptable option, click here to see if DROP may be the solution you’ve been looking for.

Your healthier alternative is here.

No needles. No restrictive diets. Just a smarter approach to weight management.

Click here to see if DROP is right for you.

Note: The information provided on this website is intended for informational purposes only and should not be considered medical advice or used as a substitute for professional healthcare guidance. It is your responsibility to comply with all applicable laws, regulations, and guidelines regarding the purchase, possession, and use of prescription medications.

The post Dr. McCullough Weighs In: The History & Future of GLP-1s appeared first on The Gateway Pundit.

previous post
WATCH: Arizona Secretary of State Adrian Fontes Says he Plans to Violate Federal Election Law – “Tell Them to Go to Hell”
next post
The Signal Chat Scandal—A Tempest in a Teacup, Not an Actionable Offense

You may also like

HILARIOUS! President Trump Calls Chuck Schumer “Our Great...

June 27, 2025

“Queer Booksellers” Owned Bookstore in San Francisco Bans...

June 27, 2025

“It May Blow This Whole Thing Open” –...

June 27, 2025

Rep. LaMonica McIver Tells Jen Psaki She ‘Never...

June 27, 2025

RIGHT ON CUE: Any And All Criticism of...

June 27, 2025

WHAT A SHAME: Harvard’s Kennedy School of Government...

June 27, 2025

Zohran Mamdani Wants to Spend $65 Million on...

June 27, 2025

Rep. Andy Ogles Urges AG Pam Bondi to...

June 27, 2025

Victor Reacts: Burn Our Flag, Nothing. Burn the...

June 27, 2025

GOP Lawmakers Erupt After Unelected Senate Parliamentarian Guts...

June 27, 2025
Join The Exclusive Subscription Today And Get Premium Articles For Free


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent Posts

  • Most People Want Teacher-Led Prayer in Public Schools—It’s Time to Choose

    June 26, 2025
  • How Should We Think About Misinformation?

    June 26, 2025
  • Fossil Fuel Subsidies Are Mostly Fiction, But the Real Energy Subsidies Should Go

    June 25, 2025
  • Overlicensed and Underused: Rethinking Pharmacy’s Role in Health Care

    June 25, 2025
  • Warren, Trump, and the Debt Limit

    June 25, 2025
  • About Us
  • Contacts
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting

Copyright © 2025 highyieldmarkets.com | All Rights Reserved

High Yield Markets
  • World News
  • Politics
  • Investing
  • Stock
  • Editor’s Pick